Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Treatment Access News

CanPrEP Submits Supplemental Recommendations on Truvada for HIV PrEP to pCPA

january 4, 2017

CanPrEP is submitting this letter as a supplement to our previous submission to the pan-Canadian Pharmaceutical Alliance on Truvada (fixed dose oral combination emtricitabine/tenofovir disoproxil fumarate; FTC/TDF) for HIV pre-exposure prophylaxis (PrEP). This supplemental submission is intended to address issues raised in the Canadian Drug Expert Committee (CDEC) final report and recommendations on Truvada as PrEP...

Click here to view the full PDF